

Wednesday, November 24, 2004

---

**7:00 – 9:30 pm**

*Foyer*

**Pre-Conference Registration**

---

**7:00 – 9:30 pm**

*Toronto 1*

**HIV Community Treatment Forum: Hot Topics – All Welcome**

*Highlights From Recent International Conferences and Observations  
in Clinical Practice*

**Moderator:** Ron Rosenes

**Speakers:** Sean Hosein  
Stanley Read  
José Sousa  
Mark Wainberg  
Jane McCall

**Presented by the Canadian AIDS Treatment Information Exchange, in cooperation with the OHTN.  
Sponsored by Boehringer Ingelheim.**

Refreshments will be provided.

---

Thursday, November 25, 2004

---

**8:00 – 9:00 am**      **Registration and Continental Breakfast**

*Foyer*

---

**8:00 am**              **PHA Lounge – open all day**

*Johnston*

---

**9:00 – 9:15 am**      **Welcome and Opening Remarks**

*Toronto I & II*

Brian Cornelson – Conference Co-Chair, St. Michael's Hospital

Sean Rourke – Conference Co-Chair, OHTN and St. Michael's Hospital

---

**9:15 – 10:00 am**

*Toronto I & II*

**Susan King Inaugural Lecture**

Stanley Read – Hospital for Sick Children

*Children and HIV/AIDS: Progress in Prevention and Management*

**Presentation to the Hospital for Sick Children *Children with AIDS Fund\****

\*Donations from Bayer HealthCare, Stanley Read, Craig McClure

---

**10:00 – 10:30 am**      **Networking and Refreshment Break**

*Foyer*

---

**10:30 – 12:00**      **Concurrent Oral Breakout Sessions**

**noon**

*Harris*

***Vulnerable Populations***

Co-Moderators: Tony Di Pede and Lynne Leonard

- 101**      Peggy Millson; Laurel Challacombe; Ted Myers; WHO Study team; NEP Study team; I-Track Study team; ***Longterm Trends In HIV Prevalence And Risk Behaviours Among Injection Drug Users In Toronto And Sudbury***
- 102**      Susan Mintz; Michelle Dagnino; Sarah Flicker; Ruth Koleszar-Green; June Larkin; Claudia Mitchell; ***AIDS; Representation And HIV Risk In Youth***
- 103**      Edith Wambayi; Carolyn Byrne; ***Determining The Most Appropriate Methods Of HIV/AIDS Prevention And Accessing Services Among Africans Living In Toronto - A Needs Assessment***
- 104**      Joyce Seto; Art Zoccole; Janice Ristock; Kevin Barlow; ***Addressing Homophobia In Relation To HIV/AIDS In Aboriginal Communities***
- 105**      Randy Jackson; Judy Mill; Frances Reintjes; Claudette Dumont-Smith; ***The Effect Of HIV-Related Stigma On Access To Health Services: Voices Of Aboriginal People Living With HIV***
- 106**      Zhaida Uddin; Chloe Healy; ***Operation Hairspray***
-

---

Concurrent Oral Breakout Sessions continued

---

Lismer

**MSM Issues**

Co-Moderators: Ted Myers and Rob MacKay

- 107 Barry Adam; John Maxwell; Chris Lau; Winston Husbands; James Murray; ***From Research To Action And Back Again: Developing Best Practices In HIV Prevention Education For Gay/Bisexual Men***
- 108 Liviana Calzavara; Sandra Gardner; Paul Corey; Wendy Medved; Ann Burchell; Robert Remis; Ted Myers; Carol Swantee; Janet Raboud; and the Polaris Study Team; ***Risk Behaviours Among HIV-Negative MSM Who Seroconverted During Follow-Up In The Polaris Cohort***
- 109 Winston Husbands; Chris Lau; Raj Maharaj; Peter Ho; James Murray; Trevor Gray; Noulmook Sutdhibhasilp; Seema Opal; Jose Cedano; ***Party Drugs In The House: Issues For HIV Prevention For Gay Clubbers In Toronto***
- 110 Peter Ho; Noulmook Sutdhibhasilp; Maurice Poon; Gina Browne; ***The Acceptability, Effectiveness And Efficiency Of A Bathhouse Outreach Programme Called Sexpert For Asian Men Who Have Sex With Men (AMSM)***
- 111 Barry D. Adam; Winston Husbands; James Murray; John Maxwell; ***Reinfection Discourses Among HIV-Positive Men***
- 112 Dennis J. Haubrich; Liviana Calzavara; Domenico Calla; Karen Ryder; Ted Myers; and the Polaris Study Team; ***Interview Accounts Of HIV Risk Events Among Gay And Bisexual Men Enrolled In The Polaris HIV Seroconversion Study***

---

Thomson

**Treatment Issues and Advances**

Co-Moderators: Sean Hosein and Anita Rachlis

- 113 Anita Rachlis; Christopher Jones; Carol Swantee; Keyi Wu; ***Appropriateness Of Antiretroviral Therapy At Initiation Of Treatment For HIV In Ontario: 2003***
- 114 Louise Balfour; Amy Silverman; Kowal John; Georgio Tasca; Jonathan Angel; Paul MacPherson; Gary Garber; Curtis Cooper; William Cameron; ***Finding The Art To Starting HAART: Informing, Empowering, And Psychologically Preparing Patients For HAART And Treatment Adherence***
- 115 Richard Harrigan; Janet Raboud; Mona Loutfy; Fiona Smail; Kevin Gough; William Cameron; Anita Rachlis; Brian Wynhoven; Julio Montaner; Sharon Walmsley; ***Genotypic Resistance Assay For Entire gp-41 Sequence With Identification Of gp-41 Polymorphisms In Enfuvirtide-Naïve Patients And New gp-41 Mutations In Patients Failing Enfuvirtide***
- 116 Marek Smieja; Eva Lonn; Fiona Smail; Lynn Kelleher; Shelley Schmidt; Sandy Smith; Serena Holmes; Wenjie Cai; Kevin Gough; Sylvie Trottier; John Gill; Marianne Harris; ***Anti-Retroviral Exposure And Carotid Intimal Medial Thickness In A Multi-Centre Canadian HIV Cohort***
-

Thursday, November 25, 2004 (continued)

---

Treatment Issues and Advances continued

---

- 117 Reza Nazari; Sadhna Joshi; **HIV-1 Entry To Lymphoid Cell Lines Is Blocked By Downregulation Of CCR5 Expression Using Multimeric Hammerhead Ribozymes**
- 118 Kenneth Lee; Kengo Asai; Alan Cochrane; **A Novel Strategy To Inhibit HIV-1 Replication**
- 

MacDonald

**Vaccines and Immunology**

Co-Moderators: Jonathan Angel and Stephanie Nixon

- 119 Y. Guan; M.A. Luscher; E. Rakasz; D.I. Watkins; T. Rustam; N. Khanna; M. Candido; B. Li; J. Tartaglia; K.S. MacDonald; **Allo-Immunization With Mamu-A\*01 And DRw201 Vaccine Failed To Protect Rhesus Macaque From Infection Of SIVmac239 Derived From Mamu-A\*01 And DRw201 Positive PBMC**
- 120 Janina Jiang; Ken Rosenthal; **Protection And Generation Of Mucosal Memory T-Cells In The Genital Tract Following Mucosal Immunization With Vesicular Stomatitis Virus Vector Expressing HIV-1gag**
- 121 Ali Azizi; Masoud Ghorbani; Majid Mojibian; David Montefiori; Francisco Diaz-Mitoma; **Immunogenicity Of Single And Combined HIV-1/HCV Candidate Vaccines In A HLA-A2.1 Murine Model**
- 122 Jacob Bukczynski; Tao Wen; Natasha Christie; Jean-Pierre Routy; Mohamed-Rachid Boulassel; Colin Kovacs; Kelly MacDonald; Mario Ostrowski; Rafick-Pierre Sekaly; Nicole F. Bernard; Tania Watts; **Distinct Costimulatory Requirements Of HIV-Specific CD8 T Cells In Recently Vs. Chronically Infected HIV+ Individuals**
- 123 Ross La Motte-Mohs; Elaine Herer; Juan Carlos Zúñiga-Pflücker; **Induction Of T Cell Development From Human Cord Blood Hematopoietic Stem Cells By Delta-like 1 In Vitro**
- 124 Charlene Young; Jonathan B. Angel; **Interleukin-7 Receptor (CD127) Expression On Thymocytes At Different Stages Of Maturation And The Effect Of IL-7, TNF- $\alpha$  And HIV Infection**
- 

10:30 am –  
12:00 noon

*Carm/Jackson*

**Workshop**

**Understanding Research – A Workshop For Non-Researchers**

Presenters: Thomas Egdorf and Lea Narciso, Ontario AIDS Network

This workshop is intended as a primer for non-scientists to enable them to better understand and absorb the information presented at the conference. Basic information regarding research methodologies and terminology will be presented. This workshop would be of benefit to those with little or no scientific background.

---

Thursday, November 25, 2004 (continued)

12:00 noon –  
1:30 pm  
Toronto I & II

**Luncheon with Invited Speaker:** Craig McClure, International AIDS Society  
*Activism and Advocacy in the Global HIV/AIDS Movement and the Case for Multi-Stakeholder Collaboration*

Activism and advocacy have fuelled an accelerated response to the HIV/AIDS epidemic, and led to the development of collaborative models for HIV research, policy and programming. This presentation will review the history of activism and advocacy in the North, and the relevance of this history to addressing the AIDS epidemic in the South. It will also examine the emergence of multi-stakeholder collaborative models of work that have emerged out of the AIDS advocacy movement, the underlying assumptions of these models, and the potential benefits and pitfalls of adapting these models for use in developing countries.

1:30 – 3:00 pm  
Foyer

**Poster Viewing – Guided Tours**

*Vaccines, Immunology, Virology (216-241)* – Ken Rosenthal  
*Global Impact of HIV, Women's and Children's Issues (242-257)* – Liviana Calzavara

3:00 – 5:00 pm  
Toronto I & II

**Plenary: Presentation and Panel Discussion**

***Expanding Horizons in HIV Prevention and Education***

**Moderator**

Frank McGee, AIDS Bureau, Ontario Ministry of Health and Long-Term Care

**Panelists**

Kevin Gough, St Michael's Hospital  
Ken Rosenthal, McMaster University  
Barry Adam, University of Windsor  
Charu Kaushic, McMaster University  
Ron Shore, Street Health Centre, Kingston

**Speakers**

**Robert Remis**, University of Toronto

***The HIV Epidemic in Ontario: 2004 Update***

The HIV epidemic in Ontario continues unabated. Based on our updated model, an estimated 23,500 persons were living with HIV infection in December 2003. HIV prevalence overall increased about 6% annually in the past 5 years with the most marked increases among persons from HIV-endemic countries and others infected heterosexually. New HIV diagnoses increased 11% in the first half of 2004 compared to 2003, related to increases in the Southwest, Central West and Northern regions (increasing 104%, 78% and 55%, respectively). This was due to increases in diagnoses among IDUs in the Southwest and Northern regions, MSM in the Southwest and Central West regions and high risk heterosexuals in the Southwest region.

Thursday, November 25, 2004 (continued)

---

*Expanding Horizons in HIV Prevention and Education continued*

---

**Kelly MacDonald**, Mount Sinai Hospital, University of Toronto

***Biological approaches to prevention of HIV/AIDS: Are we getting enough bang for our buck?***

Biological approaches to HIV prevention are more diverse than simply vaccine development. Post-exposure prophylaxis with anti-HIV drugs or biological response modifiers, treatment of co-pathogens, boosting innate immunity, and passively acquired immune protection are also possible. Biological prevention approaches have not been sufficiently considered or tested in an integrated way with other novel approaches including targeting core groups, behavioral strategies and economic motivators in terms of synergistic outcome. Furthermore, HIV biomedical researchers have not taken a broad enough view of all possible approaches or utilized the scientific progress of other scientific fields sufficiently. The promotion of "HIV exceptionalism" which initially championed HIV research has now ghettoized it by reducing scientific interplay and synergy with other scientific fields and disease sectors.

**James Murray**, AIDS Bureau

***MSM Primary and Secondary Prevention Strategies***

The bulk of new HIV and syphilis infections in gay men are with urban gay men in mid-life who are highly sophisticated about HIV risk, are aware of the seriousness of HIV infection and know how to protect themselves. For other gay men at risk, specifically men of color, we have limited information to help us understand their risk for HIV and how best to respond. This talk will consider the state of HIV prevention with gay men in Ontario, new strategies for strengthening Ontario's response, and what role HIV research can play in these efforts.

**Lynne Leonard**, University of Ottawa

***The Urgent Need to Scale-up Harm Reduction Interventions for IDUs***

Identifying injection practices and sexual behaviours associated with HIV and hepatitis C (HCV) infection among women and men who inject drugs has helped to define preventive interventions to promote individual behaviour change. However, individual HIV and HCV risk-related practices and behaviours may also be mediated by risk conditions at the relationship and community level. These risk conditions comprise factors such as limited availability of resources to initiate and maintain safer injection practices as well as access to HIV and HCV testing.

Using data from two community-based research studies among women and men in Ottawa who inject drugs, Dr Leonard will critically evaluate current harm reduction responses which may compromise the capacity of injection drug users to adopt and maintain individual HIV and HCV preventive behaviour to reduce the harm associated with injection drug use.

---

**5:00 – 6:00 pm**

*Thomson*

**CAHRO Annual General Meeting**

**Featured Speakers**

**Ken Rosenthal** will speak about current AIDS funding in Canada and possible approaches to accelerating the promised increase in funding.

**Hendrik Poinar** will speak on the origins of HIV.

---

Thursday, November 25, 2004 *(continued)*

---

**6:00 pm**

*Foyer/  
Toronto I & II*

**OHTN Reception – All Welcome**

Food and refreshments will be available.

**Silent Auction** Donated works of art and other items will be auctioned in support of the *Positive Action Fund*.

**Presentation to the *Positive Action Fund***

**Photo Essay: *The Question was: Could I find a way to live with AIDS?***

**Special Guest: Jacob Peters**

Following a warm reception to his photo essay at the XV IAC in Bangkok earlier this year, the OHTN is pleased to provide Jake with the opportunity to present, *The Question was: Could I find a way to live with AIDS?*, here in Toronto.

**AIDS 2006 Update – Mark Wainberg and Ron Rosenes**

---

Friday, November 26, 2004

---

**8:00 – 9:00 am**      **Registration and Continental Breakfast**

*Foyer*

---

**8:00 am**              **PHA Lounge – open all day**

*Johnston*

---

**8:00 – 9:00 am**      **CAHRO Meeting – Policy Discussion**

*Thomson*

A presentation and discussion of initiatives to address important HIV Research issues and promote multi-disciplinary/group efforts in examining facets of HIV/AIDS in Ontario.

**Panelists**

Alan Cochrane, Carol Major, Robert Remis, Ken Rosenthal

---

**9:00 – 11:00 am**      **Plenary: Presentations and Panel Discussion**

*Toronto I & II*

***Staying the Course in Care and Treatment***

**Moderator**

Craig McClure, International AIDS Society

**Panelists**

Gina Browne, McMaster University  
Curtis Cooper, University of Ottawa  
Rick Kennedy, Ontario AIDS Network  
Rodger MacArthur, Wayne State University  
Ed Mills, Canadian College of Naturopathic Medicine  
Derek Thazuk, Toronto PWA Foundation

**Speakers**

**Brian Cornelson**, St Michaels Hospital

***Learning to Juggle: Ongoing Long-Term Management Issues***

Thanks to the advent of highly-active antiretroviral therapy for HIV infection in the last decade, people with HIV are living longer—which is a good thing! However, they are also aging, which brings with it a multitude of degenerative conditions, and they are often developing complications due to disease progression, adverse drug reactions, and co-existing diseases such as hepatitis C. The focus of care for people living with HIV and their physicians has shifted dramatically from treating opportunistic infections and palliative care to ongoing management of a web of chronic conditions whose nature and treatment often seem to complicate the course and management of each other.

This talk will review some of the on-going management challenges of chronic HIV infection, including the need to change antiviral regimens because of direct side-effects or indirect adverse effects, and the management of hypercholesterolemia, hypertriglyceridemia, glucose intolerance and diabetes mellitus, osteoporosis, hypogonadism and anal cancer as well as constitutional symptoms such as weight loss and fatigue.

---



Friday, November 26, 2004 (continued)

---

Staying the Course in Care and Treatment Speakers continued

---

**Louise Binder**, Canadian Treatment Action Coalition

***Treatment Decision making: Is it a case of more choices but less choice***

The speaker will discuss the complexity of treatment decision making in the era of HAART and HIV coinfection, both for the treatment naive and treatment experienced patient. She will talk about the impact of recent research into new therapies as part of the decision process. She will describe particular treatment issues for different HIV infected populations including women, intravenous drug users, Aboriginal people and children. She will also explore the problem of accessing reliable and objective treatment information. Barriers to access will also be discussed, particularly in the context of the present cost containment environment of provincial health budgets.

**Jonathan Angel**, University of Ottawa

***New Horizons in HIV Care and Management***

The past ten years has seen great advances in the development of treatment for individuals with HIV infection. Newer therapies have become more compact and associated with fewer short-term toxicities. The risk of potential long-term toxicities, the need for strict compliance to lifelong therapy, and the costs associated with antiretroviral therapy, remain important issues and underscore the fact that newer approaches to the management of HIV infection are required. Ongoing development of new antiretroviral agents, including those that target different steps in the viral life cycle, novel ways of using currently available therapies, and the development of immune-based therapies, including therapeutic HIV vaccines are approaches that will hopefully result in ongoing improvement in the treatment of individuals with HIV infection.

**Sharon Walmsley**, Toronto General Hospital

***Complexities in the Management of the HIV/HCV Coinfected Patient***

The prevalence of HCV is increasing in the HIV population, and it is estimated that about 10% of HIV positive patients in Canada are coinfecting. Until recently, it was not felt important to treat the HCV infection as patients died of complications of HIV long before the liver disease from HCV became clinically apparent. However, with the improved survival of HIV with HAART, HCV related liver disease is rising as an important cause of morbidity and mortality in the co-infected patient. The current therapy for HCV is a combination of pegylated interferon given by injection once weekly with oral ribavirin given twice daily. Although cures can be realized in a small portion of treated patients, therapy is difficult. Response rates are lower than in the mono-infected patient, and adverse reaction rates and withdrawal rates are increased. New strategies are being evaluated to enable more patients to successfully receive treatment such as the use of the early viral response to predict long term outcome and the use of supportive therapies such as erythropoietin, and GM-CSF to treat the hematologic toxicities, and antidepressants to treat the mood swings associated with interferon. There still remains controversy as to which viral infection should be treated first- HIV or HCV and the pros and cons of the two approaches will be reviewed.

---

11:00 am– 12:30  
pm  
Foyer

**Poster Viewing – Guided Tours:**

*Treatment* (201- 215) – Darien Taylor

*PHA Issues, Substance Use, Vulnerable Populations, Policy Issues* (258 – 278) – TBD

---

## Friday, November 26, 2004 (continued)

---

12:30 – 1:30 pm      Luncheon with Speakers: William Flanagan and Sean Rourke  
Toronto I & II      Phase II of the OHTN

---

1:30 – 2:30 pm      Concurrent Oral Breakout Sessions  
Carm/Jackson      PHA Issues

Co-Moderators: Rick Kennedy and Roy Cain

125      Gina Browne; Robin Weir; Joan Crook; Jacqueline Roberts; Amiram Gafni;  
**Characteristics Of PHAs Who Use CBAOS' Supportive Care Services  
In Ontario: Lessons From Four Studies**

126      Tiffany Veinot; Timothy Rogers; **A Whole Greater Than Its Parts: A  
Community-Based Model For HIV/AIDS Treatment Information Exchange**

127      Sergio Rueda; Janet Raboud; Cameron Mustard; Ahmed Bayoumi; John Lavis;  
Sean B. Rourke; **Health-Related Quality Of Life Dimensions And  
Employment Status In HIV/AIDS**

128      Andrea Sharp; Robert Burgoyne; **Hunger Pains: Strategies For Meeting  
The Needs Of PHAs Living In Poverty**

---

Harris

**HIV/HCV**

Co-Moderators: Peggy Millson and Derek Thaczuk

129      Liviana Calzavara; Ann Burchell; Carol Swantee; Ted Myers; Peter Ford;  
Nancy Ramuscak; Andrea Anonychuk; Angela Francis; **Hepatitis C  
Prevalence Among Newly Admitted Male And Female Inmates In  
Ontario Jails And Detention Centres**

130      Curtis L. Cooper; Cathy Breau; David Mackie; Craig Lee; Gary Garber;  
**HAART Discontinuation For Liver Toxicity Is Rare In HIV-HCV Co-Infection**

131      Ted Myers; Dan Allman; Robert S. Remis; Ann Burchell; Carol Swantee; Liviana  
Calzavara; John Maxwell; Marguerite Ennis; **HCV Prevalence And HIV/HCV  
Co-Infection In A Diverse Provincial Sample Of Gay And Bisexual Men**

132      Lynne Leonard; Christine Navarro; Nicholas Birkett; Robert Remis;  
**The Need To Scale-Up Access To Hepatitis C Virus Testing Among  
Injection Drug Users**

---

Friday, November 26, 2004 (continued)

1:30 – 2:30 pm

**Global Impact of HIV**

MacDonald/Lismer

Co-Moderators: William Flanagan and Robert Remis

- 133 Stephanie Nixon; **Critical Public Health Ethics And HIV/AIDS: Ontario, Canada And The World**
- 134 Jillian Schuster; Jessica Cadesky; Ian Lubek; Mee Lian Wong; Sarath Kros; Bun Chhem Dy; Kate van der Riet; Srilakshmi Ganapathi; Tra Tim Ou Bory; Em Phalla Mony; **Student Internships In Cambodia (II): Sexual Tourists, Young Souvenir Vendors And HIV/AIDS Prevention Education At Angkor Wat, Cambodia**
- 135 Ann Burchell; Liviana Calzavara; Victoria Orekhovskiy; Elvira Demainenko; Marina Malysheva; Eugenia Jukova; Ekaterina Perekhodchenko; Natalia Ladnaia; **Characterization Of An Emerging Heterosexual HIV Epidemic In Russia Using A Case-Control Approach**
- 136 Dennis G. Willms; **"Conceptual Events": Advancing A Culturally Compelling Method For HIV Interventions**

Thomson

**Women's and Children's Issues**

Co-Moderators: Janet Rowe and Stanley Read

- 137 Angela M. Barbara; Dale Guenter; Randi Zlotnik-Shaul; Mark Yudin; Susan King; **Women's Experiences Of HIV Testing During Pregnancy**
- 138 Edward Mills; Gordon Guyatt; Ping Wu; Peter Brocklehurst; **Vitamin Supplementation For Prevention Of Mother-To-Child Transmission Of HIV And Pre-Term Delivery: A Systematic Review And Meta-Analysis Of RCTs Including More Than 2800 Women**
- 139 Erin MacDonald; Mary Louise Beecroft; Jen Newton; Kenneth Rosenthal; Charu Kaushic; **Interaction Of Primary Genital Epithelial Cells With Sexually Transmitted Viral Agents And Effect Of Sex Hormones On Susceptibility: Implications In Heterosexual Transmission Of HIV In Women**
- 140 Barbara Kuziora; Alison Savoy; Mary Louise Beecroft; Charu Kaushic; **Role Of Dendritic Cell Subsets In The Human Cervix And Endometrium In Heterosexual Transmission Of HIV In Women**

2:30 – 3:00 pm

**Networking and Refreshment Break**

Foyer

Friday, November 26, 2004 *(continued)*

---

**3:00 – 5:00 pm**

*Toronto I & II*

**Concurrent Workshops:**

**Grant Writing**

**Presenters:** William Cameron, Alan Cochrane, Winston Husbands, Peggy Millson, Ken Rosenthal, Sean Rourke, Sharon Walmsley

A training opportunity in the art of creating winning applications for research funding organized and presented by members of the Canadian Association of HIV Researchers – Ontario (CAHRO).

*Carm/Jackson*

**Genotyping for HIV Drug Resistance\***

**Presenters:** Rodger MacArthur, Richard Harrigan

This session is designed for clinicians, physicians and others interested in the interpretation of genotype test results for HIV drug resistance.

\* Sponsored by Abbott Molecular Diagnostics

*Thomson*

**Implementation of an Electronic Clinical Management System The Real World**

**Presenters:** Ken Burgess, William Barrie

A practical workshop presented by two primary care physicians that have done it. An invaluable presentation if you are considering a CMS for your clinical practice.

---